Closed · W81XWH-22-ALSRP-CBDA · CFDA 12.420 · Discretionary
DoD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- July 28, 2022
- Close date
- 10
- Expected awards
The verdict
DoD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 10 expected awards. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 10
- expected awards
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DoD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award - is cataloged under number W81XWH-22-ALSRP-CBDA and tied to CFDA assistance listing 12.420, posted by Defense Health Agency Contracting Activity - DHACA. Grants.gov currently shows the opportunity as closed, first posted on March 16, 2022. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. The agency has projected $8.0 million in total estimated funding for this announcement. It expects to issue 10 awards. If the agency funds the expected 10 awards from the $8.0 million estimated pool, the average award works out to roughly $800,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on July 28, 2022. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
July 28, 2022
Posted
March 16, 2022
Est. Total Funding
$8,000,000
Expected Awards
10
Instrument
Grant
Description
The intent of the FY22 ALSRP Clinical Biomarker Development Award (CBDA) is to maximize clinical ALS resources and biorepositories to better define subtypes, assess prognosis, or predict therapeutic response and to improve value of clinical trials. Applications should focus on the development and improvement of clinical biomarkers to enrich clinical trials in ALS. Biomarkers may be predictive/cohort-selective, prognostic, and/or pharmacodynamic. Biomarker development or data analysis can be relevant to a specific therapeutic or class of therapeutics, or to a specific type of ALS (such as a particular genetic mutation) and does not have to broadly apply to all patients. Analysis of results and/or biosamples collected under these projects should be made broadly available through deposition in existing publicly available curated repositories and data platforms when possible.Clinical trials are not allowed for this award mechanism. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Investigators interested in intervention clinical trials should consider applying under the FY22 ALSRP Pilot Clinical Trial Award (Funding Opportunity Number: W81XWH-22-ALSRP-PCTA). For information about other FY22 ALSRP award mechanisms, see https://cdmrp.army.mil/funding/alsrp.Use of existing well-characterized and highly curated clinical resources is encouraged. Examples of human-based ALS resources include ongoing or completed clinical trial datasets, biorepositories of clinical specimens, large transcriptome/proteome/metabolomic datasets, and databases of clinical data and/or metadata. The applicant must demonstrate availability of, and accessibility to, the necessary resources to accomplish the proposed aims. Resources should be available at the time of application submission, however, collection of new specimens and/or data from participants in an existing cohort is allowed. Applications are encouraged to include diversity in their sample populations.A list of suitable resources can be found on the ALSRP web page (https://cdmrp.army.mil/ alsrp/resources/ALSRPresources). Other resources may be used, provided they have an adequate description of repository parameters and mechanisms for broad access.Examples of studies appropriate for submission to the FY22 ALSRP Clinical Biomarker Development Award include, but are not limited to:• Using patient-based resources to link biosamples to rigorous molecular data.• Collecting and analyzing biospecimens as a companion to an anticipated/ongoing clinical trial.• Correlating clinical trial-related data (e.g., biosample analysis, imaging, or epidemiological data) with clinical outcomes or responses to therapies.Early-career investigators and/or early-career physician scientists are encouraged to apply for the FY22 ALSRP Clinical Biomarker Development Award.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |